Bio News
DPT⁺ fibroblasts have been identified as the cause of treatment resistance induced by androgen deprivation therapy (ADT) in prostate cancer, and two new targets for blocking this process have also been identified. DPT⁺ fibroblasts activate complement signaling, depleting CD8⁺ T cells and creating an immune-evasive environment. This opens the possibility of developing combination therapies that simultaneously target the DPT⁺ pathway and the new targets TSPAN1 and NRXN1.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
